Small molecule inhibitors of Ku70/80 and uses thereof
View Patent ↗Provided herein are methods for identifying and treating subjects having conditions involving aberrant Ku70/80 activity. In particular, the invention relates to small-molecules which function as inhibitors of Ku70/80 protein and the non-homologous end-joining (NHEJ) pathway, and their use as therapeutics for the treatment of cancer and other diseases.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salts, and/or solvates thereof.
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. A kit comprising a compound of claim 1 and instructions for administering said compound to a patient having a hyperproliferative disease, wherein said hyperproliferative disease is cancer.
4. The kit of claim 3 , wherein the cancer is one or more selected from glioblastoma, prostate cancer, a solid cancer, and a hematologic cancer.
5. The kit of claim 3 , wherein the cancer is characterized by aberrant Ku70/80 activity.
6. The kit of claim 3 , wherein said cancer is any type of cancer having NHEJ pathway related activity.
7. The kit of claim 3 , wherein the cancer is characterized by aberrant of DNA-PKcs activity.
8. The kit of claim 3 , further comprising one or more anticancer agents.
9. The kit of claim 8 , wherein said compound is to be administered together with one or more anticancer agents.